Stage IIIC Rectal Cancer Completed Phase 1 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0028694 (Stage IIIC Rectal Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00060411A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal CancerTreatment